Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Files to Begin Phase I Trial of Hypercholesterolemia Drug

Premium

NEW YORK (GenomeWeb) — Alnylam Pharmaceuticals this week announced that it has filed an application with UK regulators to begin a Phase I trial of ALN-PCSsc, a subcutaneously administered siRNA treatment for hypercholesterolemia.

The placebo-controlled, single-blind study is expected to enroll up to 74 individuals with elevated baseline low-density lipoprotein levels. Single ascending and multiple doses of ALN-PCSsc will be evaluated.

The study is expected to begin in late 2014 or early 2015, with initial data available by mid-2015.

ALN-PCSsc is designed to silence proprotein convertase subtilisn/kexin type 9, or PCSK9, which has been shown to regulate low-density lipoprotein receptor levels and play a role in plasma low-density lipoprotein clearance.

The drug uses Alnylam's proprietary GalNAc conjugation technology to enable subcutaneous delivery. The company has also tested a different version of the drug that uses lipid-based delivery nanoparticles, but has been focusing its efforts on GalNAc recently.

Under the terms of a 2013 deal, The Medicines Company holds the rights to both drug candidates.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.